Legend Biotech (LEGN) Current Deferred Revenue (2019 - 2024)

Legend Biotech's Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $46.9 million for Q4 2024.

• Quarterly Current Deferred Revenue fell 11.58% year-over-year to $46.9 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $46.9 million (down 11.58% YoY) and the FY2024 annual result came in at $46.9 million, down 11.58% from the prior year.
• Current Deferred Revenue was $46.9 million for Q4 2024 at Legend Biotech, down from $53.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $53.0 million in Q4 2023 and bottomed at -$60.6 million in Q4 2021.
• A 4-year average of -$3.9 million and a median of -$4.1 million in 2020 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2020 — Current Deferred Revenue sank 218.84% — and 2021, when it fell 10.23%.
• Legend Biotech's Current Deferred Revenue stood at -$55.0 million in 2020, then slipped by 10.23% to -$60.6 million in 2021, then surged by 187.41% to $53.0 million in 2023, then declined by 11.58% to $46.9 million in 2024.
• Business Quant data shows LEGN's Current Deferred Revenue at $46.9 million in Q4 2024, $53.0 million in Q4 2023, and -$60.6 million in Q4 2021.